|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Departments of Internal Medicine II, Internal
Medicine I, Vascular Biology and Thrombosis Research, and Urology,
University of Vienna, Austria; St Anna Children's Hospital, Vienna,
Austria; and Georg-August University, Goettingen, Germany.
We have recently shown that resting human mast cells (MCs) produce
tissue-type plasminogen activator (t-PA) without simultaneously expressing plasminogen activator inhibitor 1 (PAI-1). In the present study we have identified the anaphylatoxin rhC5a as a potent inducer of
PAI-1 expression in human MCs and basophils. In primary human skin MCs
and primary blood basophils, exposure to rhC5a was followed by an
increase from undetectable to significant levels of PAI-1. In addition,
rhC5a induced a concentration- and time-dependent increase in PAI-1
antigen in the MC line HMC-1 and the basophil cell line KU-812 and
increased the expression of PAI-1 mRNA in HMC-1. In conditioned media
of HMC-1 treated with rhC5a, active PAI-1 could be detected. A
simultaneous loss of t-PA activity in conditioned media from the same
cells indicated that rhC5a-induced PAI-1 was capable of inhibiting the
enzymatic activity of coproduced t-PA. Correspondingly, the levels of
t-PA-PAI-1 complexes increased in rhC5a-treated cells. When HMC-1
cells were incubated with pertussis toxin or anti-C5a receptor
antibodies, the effect of rhC5a on PAI-1 production was completely
abolished. Treatment of C5a with plasmin resulted in loss of its
ability to induce PAI-1 production in MCs. Considering the suggested
role for MCs and components of the complement system in the development
of cardiovascular diseases, we hypothesize that MCs, by producing t-PA
in a resting state and by expressing PAI-1 when activated by C5a, might
participate in the modulation of the balance between proteases and
protease inhibitors regulating tissue injury and repair in such
disease processes.
(Blood. 2002;100:517-523) Mast cells (MCs) are multifunctional effector cells
of the immune system. They are involved in a variety of physiologic and pathophysiologic processes.1-3 MCs are present in most
organ systems and are strategically located in the vicinity of blood vessels or nerves in loose connective tissue. By releasing vasoactive mediators such as histamine, prostaglandin D2, vascular
endothelial growth factor, tryptase, or tumor necrosis factor- Recently, we and others have shown that in addition to the
above-mentioned compounds, MCs produce significant amounts of
tissue-type plasminogen activator (t-PA) and thus play a potential role
in endogenous fibrinolysis.12,13 It is generally assumed
that the serine proteases t-PA and urokinase type PA (u-PA) are major regulators of plasmin activation and consecutive fibrin degradation. PA
inhibitors, namely PAI-1, PAI-2, and protein C inhibitor (PAI-3), are
physiologic inhibitors of t-PA and u-PA and can neutralize the
enzymatic activities of these PAs by complex formation. With regard to
MC, it was found that resting cells express t-PA in a constitutive
manner without producing PAIs.12 Thus, t-PA is secreted in
its free and enzymatically active form by these cells. This is in
contrast to other (peri)vascular cells thought to be involved in
fibrinolysis, such as endothelial cells, smooth muscle cells, or
macrophages. In fact in vitro these cells produce significant amounts
of PAIs sufficient to inhibit the enzymatic activity of coproduced
PAs.14-17
More recently, however, it was found that human MCs treated with
phorbol ester and calcium ionophore can produce significant amounts of
PAI-1 and thus can be converted from a profibrinolytic to an
antifibrinolytic phenotype.18 This is of particular
interest because new studies with gene-deficient mice suggest that such changes in the fibrinolytic profile on a cellular level might modulate
tissue injury and repair processes (eg, in the development of
cardiovascular disease).19
Activation of the complement cascade is a major aspect of chronic
inflammatory processes that, among other effects, might also result in
vascular injury. This hypothesis has been supported by the fact that
components of the complement system have been identified in vascular
lesions such as atherosclerotic plaques.20-22 Distinct
components of the complement system mediate activation of MCs and other
leukocytes and thereby may contribute to inflammatory and vascular
disease processes. Moreover, a role for MCs in the development of
cardiovascular diseases has also been established.23-27
It was, therefore, the aim of the present study to investigate whether
components of the complement system could act as natural regulators of
the fibrinolytic system of MCs and thus, through such effects,
might contribute to the modulation of vascular injury and repair.
Materials
Cell culture
Cell lines.
The human mast cell line HMC-1 was provided by J. H. Butterfield
(Mayo Clinic, Rochester, MN).29 HMC-1 was cultured in IMDM supplemented with 10% FCS and antibiotics at 37°C and in an
atmosphere of 95% air and 5% CO2. The human basophil cell
line KU-812 was kindly provided by K. Kishi (Nijgata University,
Nijgata, Japan) and cultured in RPMI 1640 supplemented with 10% FCS
and antibiotics at 37°C and in an atmosphere of 95% air and
5%CO2.
Isolation of primary human skin mast cells.
Foreskin was obtained from 4 children undergoing circumcision. Informed
consent was obtained from parents before surgery. Resected skin
specimens were transported to the laboratory immediately after
resection. Cutaneous mast cells were purified according to published
techniques.30 In a first step, tissue was cut into small
pieces, washed in Tyrode buffer, and incubated in collagenase type 2 (2 mg/mL) for 240 minutes at 37°C. After digestion, cells were
recovered, washed, and kept in RPMI 1640 medium supplemented with 10%
FCS at 37°C for 12 hours. Skin mast cells were then washed, preincubated in AB serum, and incubated with the phycoerythrin (PE)-labeled mAb YB5.B8 (CD117) for 30 minutes at 4°C. After
washing, MCs were sorted on a FACS Vantage-SE (Becton Dickinson, San
Jose, CA) to a purity of more than 98%.
Isolation of primary human peripheral blood basophils.
Blood basophils were obtained from 3 patients with chronic myeloid
leukemia (CML) in accelerated phase after informed consent was given.
Mononuclear blood cells (MNCs) were isolated by density centrifugation
using Ficoll-Hypaque (density, 1.077). MNCs contained 60% basophils,
as assessed by Giemsa staining of a cytospin slide. Basophils were
cultured in RPMI 1640 medium supplemented with 10% FCS and 10 ng/mL of
recombinant human IL-3 (rhIL-3) (Strathmann Biotech, Hannover, Germany)
at 37°C for 7 days. Conditioned media were harvested on day 0 (60%
basophils), day 3 (65% basophils), day 5 (70% basophils), and day 7 (70% basophils). Blood basophils were isolated from 3 healthy donors
and sorted by flow cytometry to a purity of more than 98% by using mAb
97A6 as described.31 The viability of these cells as
judged by trypan blue exclusion was more than 90% in all cases.
Treatment of cells with complement components
Treatment of cells with pertussis toxin Cells (1 × 106/mL) were incubated for 120 minutes at 37°C with 0.5 µg/mL PTX in Ultraculture (BioWhittaker) medium. Thereafter the cells were washed, resuspended in Ultraculture (BioWhittaker) medium, and seeded into 24-well plates at a density of 1 × 106 cells/mL. Then rhC5a was added at concentrations indicated, and the cells were incubated for 24 hours.Plasmin treatment of rhC5a Plasmin was immobilized to CnBr-activated Sepharose 4B at a concentration of 0.5 mg/mL Sepharose according to the manufacturer's protocol. As a control, BSA was bound to CnBr-activated Sepharose at the same concentration under the same conditions. rhC5a was added to Sepharose, yielding a final concentration of 5.0 µM, and was incubated for 1 hour at 37°C. At the same concentration, rhC5a was incubated under the same conditions without Sepharose.Plasminogen activator inhibitor-1 antigen assays PAI-1 antigen in conditioned media was determined by a specific enzyme-linked immunosorbent assay (ELISA) using mAbs (Technoclone, Vienna, Austria). The PAI-1 ELISA measures active, complexed, and latent PAI-1.Assay for determination of tissue-type plasminogen activator activity and antigen t-PA activity and antigen in conditioned media were determined by a combined activity and antigen ELISA measuring t-PA activity and antigen in the same sample according to the manufacturer's protocol (Technoclone, Vienna, Austria).32Assay for determination of t-PA-PAI-1 complexes t-PA-PAI-1 complexes were measured in conditioned media using a specific, modified ELISA. This assay does not measure free PAI-1 or t-PA (Technoclone).33Assay for determination of free active PAI-1 Free, active PAI-1 was measured in conditioned media using a specific, modified ELISA. This assay does not measure latent PAI-1 or complexed PAI-1 (Technoclone).33Northern blots Total cellular RNA was prepared by the guanidinium thiocyanate-phenol-chloroform extraction from cells treated as indicated. RNA samples were electrophoresed in 1.2% agarose gels, transferred to a Duralon-UV membrane (Stratagene, La Jolla, CA). Hybridizations were performed overnight in 50 mM PIPES, 100 mM NaCl, 50 mM sodium phosphate, 1 mM EDTA, 5% sodium dodecyl sulfate containing 106 cpm/mL of the 32P-labeled cDNA probes for human PAI-1, t-PA, or rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH). After hybridization, the membranes were washed in 5% sodium dodecyl sulfate (SDS), 1 × SSC [0.15 M sodium chloride, 0.015 M sodium citrate, pH = 7.0], at room temperature for 10 minutes, then washed in the same buffer 3 times at 57°C for 20 minutes. Autoradiography was performed with XAR-5 x-ray films (Eastman Kodak, Rochester, NY) at 70°C.34
Statistical analysis Data were compared statistically by performing a Student t test for paired observations. P < .05 was considered significant.
rhC5a stimulates PAI-1 expression in primary human skin mast cells, in primary human basophils, HMC-1 cells, and KU-812 cells As can be seen from Table 1, rhC5a significantly increased PAI-1 production in primary human skin mast cells isolated from 4 different donors, in primary human blood basophils isolated from 3 healthy donors, and from 3 patients with CML, respectively, as well as in the human mast cell line HMC-1 and in the human basophil cell line KU-812. When primary human skin mast cells from 2 donors, primary human blood basophils from 2 healthy donors, HMC-1, and KU-812 cells were incubated with 1.0 µM C5a isolated from human plasma, PAI-1 production in these cells was stimulated to an extent similar to that seen when these cells were treated with rhC5a at the same concentration. rhC3a induced only a slight increase in PAI-1 production in HMC-1 and KU-812 cells. A marginal increase in PAI-1 was also induced by rhC3a in human blood basophils isolated from patients with CML incubated for 5 and 7 days in the presence of IL-3. No effect of rhC3a was seen on PAI-1 production in primary human skin mast cells or in primary human blood basophils from healthy donors. The complement components C4, C6, C7 C8, and C9, used at a concentration of 1.0 µM, had no effect on PAI-1 production in HMC-1 cells and KU-812 cells or in blood basophils from patients with CML (data not shown).
rhC5a stimulates PAI-1 expression in HMC-1 cells without affecting t-PA expression As can be seen from Figure 1A, rhC5a dose dependently stimulated PAI-1 antigen production in HMC-1 cells. Maximum stimulatory effects were seen at a concentration of 1.0 µM rhC5a. In conditioned media harvested from HMC-1 cells incubated without the addition of rhC5a, PAI-1 levels were less than 0.2 ng/mL (the detection limit of the PAI-1 antigen ELISA used was greater than 0.2 ng/mL). At concentrations greater than 0.1 µM rhC5a, active PAI-1 could be measured in the same samples. t-PA antigen was not affected by rhC5a, as shown in Figure 1B. In contrast, t-PA activity in the same samples was reduced dose dependently by rhC5a and disappeared completely at a concentration of 0.5 µM rhC5a. t-PA-PAI-1 complexes increased dose dependently in the conditioned media of such treated HMC-1 (Figure 1C). When HMC-1 cells were incubated in the absence and presence of rhC5a at a concentration of 0.5 µM for 4, 8, and 24 hours, a significant increase in total PAI-1 antigen and active PAI-1 at all time points tested was seen compared with values seen in untreated control cells. t-PA antigen measured at these time points was not affected by rhC5a. t-PA activity was reduced compared with activity in the conditioned media of untreated control cells at 4 hours of incubation and disappeared completely in the conditioned media of cells treated with rhC5a after 8 and 24 hours of incubation (data not shown).
These results were also reflected on the level of mRNA expression as
determined by Northern blotting. Significant amounts of PAI-1 specific
mRNA were present in HMC-1 cells treated with rhC5a, whereas
PAI-1-specific mRNA was not detected in HMC-1 cells incubated in the
absence of rhC5a. In contrast, t-PA-specific mRNA remained unaffected
by rhC5a in HMC-1 cells (Figure 2).
rhC5a stimulates PAI-1 in KU-812 cells Similar to the results obtained with HMC-1, rhC5a concentration- and time-dependently stimulated PAI-1 antigen production in KU-812 cells. Maximum stimulatory effects were seen at a concentration of 0.2 µM rhC5a (Figure 3A-B). t-PA was not detected in the conditioned media of KU-812 cells using an ELISA with a detection limit of 0.2 ng/mL (data not shown).
Up-regulation of PAI-1 production by rhC5a is pertussis toxin sensitive To determine whether the rhC5a-induced increase of PAI-1 production in HMC-1 cells is PTX sensitive, these cells were treated with PTX before incubation with rhC5a, as described in "Materials and methods." As can be seen from Figure 4A, pretreatment of HMC-1 cells with PTX before the addition of rhC5a completely abolished the stimulatory effect of rhC5a on PAI-1 production. PTX treatment did not affect t-PA production in these cells (data not shown).
rhC5a-induced PAI-1 production in HMC-1 cells is mediated by C5aR/CD88 To determine the specificity of the rhC5a-induced increase in PAI-1 production, we studied the effect of a mAb against C5aR/CD88 on PAI-1 production in HMC-1 cells treated with rhC5a. The stimulatory effect of rhC5a on PAI-1 production in these cells was completely blocked by preincubation of the cells with anti C5aR/CD88 mAbs. Preincubation with mAbs against CD123 used as a control did not affect PAI-1 production induced by rhC5a (Figure 4B). Treatment of the cells with the anti C5aR/CD88 antibody did not affect t-PA production in these cells (data not shown).PAI-1 stimulatory activity of rhC5a is plasmin sensitive To study the effect of plasmin on the capability of rhC5a to induce PAI-1 expression in HMC-1 cells, we treated rhC5a with plasmin immobilized to Sepharose 4B. As can be seen from Figure 4C, rhC5a pretreated with plasmin did not stimulate PAI-1 production in HMC-1 cells, whereas rhC5a pretreated with BSA immobilized to Sepharose 4B used as a control stimulated PAI-1 production to an extent similar to that for untreated rhC5a.
Mast cells produce and secrete a variety of vasoactive and proinflammatory mediators and thereby play an important role in diverse physiologic and pathophysiologic processes including cardiovascular disorders or inflammation.1-11 In addition, MCs have recently been implicated in the process of endogenous fibrinolysis.12 In particular, it was found that resting human MCs constitutively produce and secrete t-PA in its active form without simultaneously producing PAIs. Secretion of active, uncomplexed tPA appears to be a unique feature of MC because other microenvironmental cells, such as endothelial and smooth muscle cells, produce more PAIs than PAs, at least when studied in vitro.14-17 More recently, it has been shown that MCs under certain conditions may also produce PAIs. In fact, MCs stimulated with phorbol ester or calcium ionophore were found to secrete significant amounts of PAI-1.18 It was unclear, however, whether, apart from experimental compounds, natural (physiologic) stimulators of PAI-1 expression in MC also exist. In the present study, we have identified the anaphylatoxin C5a as a natural inducer of PAI-1 expression in primary human foreskin MCs, which, in contrast to other normal tissue MCs, are known to express functional C5aR/CD88.27 When these cells were incubated with rhC5a, a significant amount of PAI-1 could be detected in the conditioned media, whereas no PAI-1 was seen in untreated control cells. The possibility that non-MC-type accessory cells were induced to produce PAI-1 in these cell suspensions could be excluded because the purity of the MCs amounted to more than 98%. Another important issue to be addressed was whether other cell types known to express C5aR/CD88, would also produce PAI-1 in response to rhC5a. Blood basophils share many phenotypic and functional properties with MCs and are also known to express C5aR/CD88.29 In the present study, significant levels of PAI-1 could be detected in conditioned media prepared from CML basophils or primary blood basophils from healthy donors after exposure to rhC5a, whereas PAI-1 was not detectable in supernatants recovered from untreated cells. Similar results were obtained with the human mast cell line HMC-1 and the human basophil cell line KU-812, derived from a patient with CML patient. Other components of the complement system, such as C4, C6, C7 C8, and C9, had no effect on PAI-1 production in these cells, whereas rhC3a caused only a slight increase in PAI-1 in blood basophils, HMC-1, and KU-812 cells, respectively. The stimulating effect of rhC5a on PAI-1 production was further studied in the human MC line HMC-1, which is a useful tool for analyzing the biology of fibrinolysis-associated molecules in human MCs. In fact, like normal MCs, HMC-1 cells produce t-PA in a constitutive manner without producing PAIs.12 When HMC-1 cells were treated with increasing amounts of rhC5a, a concentration-dependent increase of PAI-1 in the conditioned media was seen. Maximum effects were observed with 1 µM rhC5a. It should be emphasized that C5a isolated from human plasma stimulated PAI-1 in these cells to an extent similar to that produced when the cells were treated with recombinant C5a. Furthermore, the effect seen with recombinant C5a was not due to endotoxin contamination of the product because endotoxin was not detectable in the purified rhC5a used in this study. To investigate whether the increase in PAI-1 brought about by rhC5a would be sufficient to inhibit t-PA activity produced by these cells, we used a combined ELISA that allowed us to determine t-PA activity and total t-PA antigen in the same sample. Although t-PA antigen production was not affected by the treatment of HMC-1 cells with rhC5a, a concentration-dependent decrease in t-PA activity was seen when these cells were incubated with increasing amounts of rhC5a. This decrease in t-PA activity showed an inverse relationship to the increase in PAI-1 in the same samples. In fact, in cells treated with rhC5a at concentrations higher than 0.5 µM, no t-PA activity could be detected, whereas active PAI-1 was still present in these samples as determined by an ELISA specific for active PAI-1. This indicates an excess production of PAI-1 over t-PA under these conditions. Moreover, by using an ELISA specific for t-PA-PAI-1 complexes, we could demonstrate an increase of these complexes in the conditioned media of mast cells treated with increasing levels of rhC5a. Thus, we conclude that PAI-1 secreted by HMC-1 cells after treatment with rhC5a by the formation of complexes with the constitutively secreted t-PA inhibits its enzymatic activity and thus changes the profibrinolytic profile of these cells under resting conditions into antifibrinolytic 1 when incubated with the anaphylatoxin C5a. The effect of rhC5a on the fibrinolytic system of HMC-1 cells was also time dependent. A significant increase in total and active PAI-1 was seen at 4, 8, and 24 hours in the conditioned media of HMC-1 cells treated with rhC5a. Total t-PA was not affected by such treatment, whereas t-PA activity was significantly reduced in cells incubated with rhC5a for 4 hours and could not be detected in the conditioned media harvested from such cells at 8 and 24 hours. In addition, rhC5a-treated HMC-1 cells exhibited significant levels of PAI-1 mRNA, but in untreated cells PAI-1 mRNA was not detectable. In contrast, rhC5a did not affect the levels of tPA-specific transcripts. The effects of C5a on its target cells are considered to be exerted through its specific cell surface receptor, namely C5aR/CD88. To investigate whether the increase in PAI-1 production is dependent on a specific interaction between rhC5a and its receptor, we treated HMC-1 cells with a blocking anti-C5aR/CD88 mAb before adding rhC5a. In these experiments, pretreatment of cells with anti-C5aR/CD88 mAb indeed blocked the rhC5a-induced expression of PAI-1, whereas a control mAb against CD123 showed no effect. From these data we conclude that the interaction of rhC5a with its receptor is necessary to induce PAI-1 production. Receptor involvement was confirmed by experiments using PTX. In fact, C5aR/CD88 belongs to the 7-transmembrane receptor subfamily of Gi-coupled receptors. In line with this notion, various C5a-induced leukocyte-reactions, such as degranulation or chemotaxis, are known to be PTX sensitive.35-37 In the present study, we show also that the rhC5a-induced up-regulation of PAI-1 expression in HMC-1 cells is PTX sensitive, indicating that this effect is also modulated through Gi-coupled receptors. The functional consequences of C5a-induced up-regulation of PAI-1 in these cells may be manifold. With regard to the complement system, one interesting aspect is that plasmin is capable of degrading C5a with consecutive loss of its biologic activity. Similarly, plasmin-treated C5a is no longer capable of inducing chemotaxis or degranulation in leukocytes.38 In the present study, we analyzed the inhibitory effect of plasmin treatment on the ability of rhC5a to increase PAI-1 expression in HMC-1 cells. Indeed, when incubated with plasmin immobilized to Sepharose, rhC5a was found to lose its PAI-1-inducing effect. Thus, one could speculate that C5a prevents its own inactivation by inhibiting plasmin generation through the up-regulation of PAI-1 expression, which in turn inactivates the simultaneously produced activator of plasminogen, t-PA. With regard to fibrinolysis, the rhC5a-induced change of MCs from potent profibrinolytic cells to antifibrinolytic cells may be of major importance. In fact, in recent studies we were able to show that resting MCs act fibrinolytically by expressing enzymatically active t-PA without simultaneously producing a PA inhibitor.12 Based on these results, we proposed a role for MCs in endogenous fibrinolysis. In the current study, we show that under distinct pathophysiologic conditions involving the complement system, the profibrinolytic phenotype of MCs may change. Such change may be of importance in chronic inflammation affecting the complement system and C5aR/CD88-bearing target cells. Recent data have shown that MCs are heterogeneous cells in terms of complement-receptor expression.22 In particular, C5aR/CD88 is only expressed on distinct subtypes of MCs, including primary foreskin MCs, a subfraction of cardiac MCs, synovial MCs in rheumatoid arthritis, and neoplastic MCs in patients with mast cell neoplasms.30 By contrast, lung MCs or MCs in other visceral organs do not express C5aR. Therefore, the up-regulation of PAI-1 in MCs may strongly depend on the subtype of MC and the specific disease. Similarly, it has been shown that synovial MCs express C5aR whereas synovial MCs in osteoarthritis do not.39 In this regard it is also noteworthy that C5a has been implicated as a specific pathogenic factor in diverse types of chronic inflammatory diseases. Based on numerous studies, a role for MCs in the development of cardiovascular diseases has also been established.23-25 In addition, complement activation is a major aspect of chronic inflammatory processes predisposing for the development of atherosclerosis, and C5a activation of MCs and other leukocytes has been implicated in this disease process.20-22,26,27 In this respect it is also of interest that, as mentioned above, C5a receptor expression on MCs is no longer seen only as a marker for mast cell heterogeneity but seems to correlate with MC activation.33 Recent evidence obtained in studies with gene-deficient mice suggests that the fibrinolytic system is not only involved in the lysis of blood clots, it plays also a role in cardiovascular injury and repair processes, thereby modulating the development of cardiovascular disease.19 In these studies it could be shown that, determined by their spatio-temporal expression, PAs are mainly involved in processes requiring matrix degradation such as cell migration and proliferation, whereas PAI-1, by inhibiting these proteases, prevents the excessive proteolytic cleavage of matrix. Thus our results, taken together with studies suggesting a role for mast cells and components of the complement system in the development of cardiovascular disease, led us to hypothesize that mast cells, by producing t-PA in a resting state and by expressing PAI-1 when activated by C5a, might participate in the modulation of the balance between proteases and protease inhibitors regulating tissue injury and repair in these disease processes. Finally, based on the observation that C5a is sensitive to cleavage and
inactivation by plasmin, it is tempting to speculate that C5a
up-regulates PAI-1 expression in mast cells and basophils to prevent
its own inactivation in an autocrine or a paracrine fashion. In such an
autocrine or paracrine loop, PAI-1 induced in these cells by C5a would
inactivate PAs
We thank Thomas Nardelli for the fine artwork.
Submitted September 20, 2001; accepted March 5, 2002.
Supported by the Ludwig Boltzmann Foundation for Cardiovascular Research and the Austrian Fund for the Promotion of Scientific Research (FWF; grant F-005-01 and F-005-09).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Johann Wojta, Department of Internal Medicine II, University of Vienna, A-1090 Vienna, Waehringer Guertel 18-20, Austria; e-mail: johann.wojta{at}univie.ac.at.
1. Galli SJ. Biology of disease: new insights into "the riddle of the mast cells": microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest. 1990;62:5-33[Medline] [Order article via Infotrieve]. 2. Dvorak AM. Basophils and mast cells: piecemeal degranulation in situ and ex vivo: possible mechanism for cytokine-induced function in disease. In: Coffey RG, ed. Granulocyte response to cytokines. Vol 1. New York, NY: Marcel Dekker; 1992:169-187. 3. Schwartz LB. The mast cell. In: Kaplan AP, ed. Allergy. Vol 1. Edingburgh: Churchill Livingstone; 1985:53-92. 4. Yano H, Wershil BK, Arizono N, Galli SJ. Substance P-induced augmentation of cutaneous vascular permeability and granulocyte infiltration in mice is mast cell-dependent. J Clin Invest. 1989;84:1276-1286[Medline] [Order article via Infotrieve].
5.
Zhang Y, Ramos BF, Jakschik BA.
Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis.
Science.
1992;258:1957-1959
6.
Klein LM, Lavker RM, Matis WL, Murphy GF.
Degranulation of human mast cells induces an endothelial cell antigen central to leukocyte adhesion.
Proc Natl Acad Sci U S A.
1989;86:8972-8976
7.
Malaviya R, Ikeda T, Ross E, Abraham SN.
Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF- 8. Serafin WE, Austen KF. Mediators of immediate hypersensitivity reactions. N Engl J Med. 1987;317:30-34[Medline] [Order article via Infotrieve].
9.
Irani AM, Schechter NM, Craig SS, Deblois G, Schwartz LB.
Two human mast cell subsets with distinct neutral protease compositions.
Proc Natl Acad Sci U S A.
1986;83:4464-4468 10. Plaut M, Pierce JH, Watson CJ, Hanle-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature. 1989;339:64-67[CrossRef][Medline] [Order article via Infotrieve].
11.
Burd PR, Rogers HW, Gordon JR, et al.
Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines.
J Exp Med.
1989;170:245-257
12.
Sillaber C, Baghestanian M, Bevec D, et al.
The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis.
J Immunol.
1999;162:1032-1041
13.
Nakajima T, Matsumoto K, Suto H, et al.
Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells.
Blood.
2001;98:1127-1134 14. Van Hinsbergh VWM. Regulation of synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis. 1988;18:307-327[Medline] [Order article via Infotrieve].
15.
Pearson JD.
Normal endothelial cell function.
Lupus.
2000;9:183-188 16. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis. 1991;5:197-206[CrossRef]. 17. Wojta J, Gallicchio M, Zoellner H, et al. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost. 1993;70:469-474[Medline] [Order article via Infotrieve].
18.
Cho SH, Tam SW, Demissie-Sanders S, Filler SA, Oh CK.
Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma.
J Immunol.
2000;165:3154-3161 19. Carmeliet P, Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol. 2000;190:387-405[CrossRef][Medline] [Order article via Infotrieve].
20.
Yasojima K, Schwab C, McGeer EG, McGeer PL.
Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques.
Arterioscler Thromb Vasc Biol.
2001;21:1214-1219 21. Niculescu F, Rus H, Cristea A, Vlaicu R. Localization of the terminal C5b-9 complement complex in the human aortic atherosclerotic wall. Immunol Lett. 1985;10:109-114[CrossRef][Medline] [Order article via Infotrieve]. 22. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol. 1999;36:949-955[CrossRef][Medline] [Order article via Infotrieve].
23.
Laine P, Kaartinen M, Penttilae A, Panula P, Paavonen T, Kovanen PT.
Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery.
Circulation.
1999;99:361-369 24. Kelley JL, Chi DS, Abou-Auda W, Smith JK, Krishnaswamy G. The molecular role of mast cells in atherosclerotic cardiovascular disease. Mol Med Today. 2000;6:304-308[CrossRef][Medline] [Order article via Infotrieve]. 25. Marone G, de Crescenzo G, Adt M, Patella V, Arbustini E, Genovese A. Immunological characterization and functional importance of human heart mast cells. Immunopharmacol. 1995;31:1-18[CrossRef][Medline] [Order article via Infotrieve]. 26. Ito RB, Engler RL, Del Balzo U. Role of cardiac mast cells in complement C5a-induced myocardial ischemia. Am J Physiol. 1993;264:H1346-H1354[Medline] [Order article via Infotrieve]. 27. Chakraborti T, Mandal A, Mandal M, Das S, Chakraborti S. Complement activation in heart diseases: role of oxidants. Cell Signal. 2000;12:607-617[CrossRef][Medline] [Order article via Infotrieve]. 28. Zwirner J, Goetze O, MoSeries A, et al. Blood- and skin-derived monocytes/macrophages respond to C3a but not to C3a (desArg) with a transient release of calcium via a pertussis sensitive signal transduction pathway. Eur J Immunol. 1997;27:2317-2322[Medline] [Order article via Infotrieve]. 29. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345-355[CrossRef][Medline] [Order article via Infotrieve]. 30. Fuereder W, Agis H, Willheim M, et al. Differential expression of complement receptors on human basophils and mast cells. J Immunol. 1994;155:3152-3160.
31.
Buhring HJ, Seiffert M, Giesert C, et al.
The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3.
Blood.
2001;97:3303-3305 32. Wojta J, Turcu L, Wagner OF, Korninger C, Binder BR. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies. J Lab Clin Med. 1987;109:665-671[Medline] [Order article via Infotrieve].
33.
Carroll VA, Griffiths MR, Geiger M, et al.
Plasma protein C inhibitor is elevated in survivors of myocardial infarction.
Arterioscler Thromb Vasc Biol.
1997;17:114-118
34.
Zhang WJ, Wojta J, Binder BR.
Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice.
Arterioscler Thromb Vasc Biol.
1997;17:465-474 35. El-Lati SG, Dahinden CA, Church MK. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol. 1994;102:803-806[CrossRef][Medline] [Order article via Infotrieve].
36.
Hartmann K, Henz BM, Krueger-Krasagakes S, et al.
C3a and C5a stimulate chemotaxis of human mast cells.
Blood.
1997;89:2863-2870 37. Nilsson G, Johnell M, Hammer CH, et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol. 1996;157:1693-1698[Abstract].
38.
Higazi AAR, Barghouti II.
Inactivation of human anaphylatoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line.
J Biol Chem.
1994;269:25529-25533 39. Kiener H, Baghestanian M, Dominkus M, et al. Expression of C5a-receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:233-245[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. Salmon and P. de Groot Pathogenic role of antiphospholipid antibodies Lupus, May 1, 2008; 17(5): 405 - 411. [Abstract] [PDF]
|
|
|
|
 |
|
 S. P. Kastl, W. S. Speidl, C. Kaun, K. M. Katsaros, G. Rega, T. Afonyushkin, V. N. Bochkov, P. Valent, A. Assadian, G. W. Hagmueller, et al. In Human Macrophages the Complement Component C5a Induces the Expression of Oncostatin M via AP-1 Activation Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 498 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ritis, M. Doumas, D. Mastellos, A. Micheli, S. Giaglis, P. Magotti, S. Rafail, G. Kartalis, P. Sideras, and J. D. Lambris A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways J. Immunol., October 1, 2006; 177(7): 4794 - 4802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Tschopp, N. Spiegl, S. Didichenko, W. Lutmann, P. Julius, J. C. Virchow, C. E. Hack, and C. A. Dahinden Granzyme B, a novel mediator of allergic inflammation: its induction and release in blood basophils and human asthma Blood, October 1, 2006; 108(7): 2290 - 2299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kanamaru, L. Scandiuzzi, M. Essig, C. Brochetta, C. Guerin-Marchand, Y. Tomino, R. C. Monteiro, M. Peuchmaur, and U. Blank Mast Cell-Mediated Remodeling and Fibrinolytic Activity Protect against Fatal Glomerulonephritis J. Immunol., May 1, 2006; 176(9): 5607 - 5615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takeshita, M. Hayashi, S. Iino, T. Kondo, Y. Inden, M. Iwase, T. Kojima, M. Hirai, M. Ito, D. J. Loskutoff, et al. Increased Expression of Plasminogen Activator Inhibitor-1 in Cardiomyocytes Contributes to Cardiac Fibrosis after Myocardial Infarction Am. J. Pathol., February 1, 2004; 164(2): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. V. Offersen, B. S. Nielsen, G. Hoyer-Hansen, F. Rank, S. Hamilton-Dutoit, J. Overgaard, and P. A. Andreasen The Myofibroblast Is the Predominant Plasminogen Activator Inhibitor-1-Expressing Cell Type in Human Breast Carcinomas Am. J. Pathol., November 1, 2003; 163(5): 1887 - 1899. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
(TNF-
) and active PAI-1 (A, 
), total t-PA
antigen (B, 
)
or presence of 0.2 µM rhC5a (
for example, t-PA secreted by mast cells